Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.42 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.42 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | USP1 | O94782 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746678 | 0.84 | HSP90AA1 (0.56) | HSP90AA1HSP90B1TRAP1HSP90AB1THRA | |
| SCHEMBL6747027 | 0.82 | HRH3 (0.42) | HSP90AA1HSP90B1HSP90AB1ESR1 | |
| SCHEMBL6746760 | 0.82 | HSP90AA1 (0.43) | HSP90AA1HSP90B1TRAP1HSP90AB1THRA | |
| SCHEMBL6746992 | 0.81 | HRH3 (0.47) | ESR1 | |
| SCHEMBL3991555 | 0.81 | HSP90AA1 (0.42) | HSP90AA1HSP90B1TRAP1HSP90AB1USP1 | |
| SCHEMBL6747037 | 0.80 | ALDH1A1 (0.41) | HSP90AA1HSP90AB1ESR1KCNH2 | |
| SCHEMBL6747116 | 0.79 | HRH3 (0.47) | HSP90AA1HSP90B1TRAP1HSP90AB1KCNH2 | |
| SCHEMBL6747087 | 0.79 | MEN1 (0.49) | HSP90AA1HSP90B1TRAP1HSP90AB1ESR1 | |
| SCHEMBL6746919 | 0.79 | HSP90AA1 (0.38) | HSP90AA1HSP90B1TRAP1HSP90AB1ESR1 | |
| SCHEMBL6747077 | 0.78 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1ESR1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038262-B1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20130072461-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072461-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8329736-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329736-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8183384-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183384-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| WO-2007139968-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90B1 2/4885TRAP1 7/4885 |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90B1 2/4885TRAP1 7/4885 |
| US-20130072461-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90B1 2/4885TRAP1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.